3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
24
Gastrointestinal
11
Head & Neck
5
Genitourinary
5
Thoracic
4
Tumor-Agnostic
3
CNS
3
Other hematologic neoplasm
2
Lymphoid
2
Gynecologic
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Breast
1
Conditions
Microsatellite Unstable Colorectal Cancer
1
Interventions
pembrolizumab
75
Injections
67
Carboplatin
38
Pemetrexed
29
Cisplatin
29
Nivolumab
27
Specimen Handling
24
Interviews as Topic
24
Cyclophosphamide
24
atezolizumab
21
tislelizumab
20
Bevacizumab
20
Paclitaxel
19
Standard of Care
16
Practice Guidelines as Topic
16
fludarabine
15
Docetaxel
15
toripalimab
14
Ipilimumab
14
Educational Status
14
Cetuximab
14
Fluorouracil
13
Oxaliplatin
12
Etoposide
12
olaparib
11
durvalumab
11
Methods
11
Gemcitabine
11
Early Intervention, Educational
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
relatlimab
×
Other solid neoplasm
×
1 year
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA